Belite Bio CSO sells 1,000 ADS under trading plan

Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions on April 28, 2026.

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions on April 28, 2026. The ADS were sold in multiple small trades at weighted average prices ranging from $154.62 to $162.59 per ADS.

The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on December 10, 2025, indicating they were scheduled in advance. Following these transactions, he directly owned 6,666 ADS of the company.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares

Net Sell 9 txns

Insider MATA NATHAN L.

Role Chief Scientific Officer

Sold 1,000 shs ($159K)

Type	Security	Shares	Price	Value
Sale	American depositary share	12	$154.6467	$2K
Sale	American depositary share	8	$155.3588	$1K
Sale	American depositary share	53	$156.6117	$8K
Sale	American depositary share	222	$157.487	$35K
Sale	American depositary share	62	$158.7107	$10K
Sale	American depositary share	380	$159.4192	$61K
Sale	American depositary share	120	$160.2742	$19K
Sale	American depositary share	89	$161.7207	$14K
Sale	American depositary share	54	$162.1424	$9K

Holdings After Transaction: American depositary share — 6,666 shares (Direct)

Footnotes (11)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. F3. Represents the weighted average price of shares sold at prices that ranged from $154.62 to $154.78. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. F4. Represents the weighted average price of shares sold at prices that ranged from $155.205 to $155.41. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. F5. Represents the weighted average price of shares sold at prices that ranged from $156.32 to $156.95. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. F6. Represents the weighted average price of shares sold at prices that ranged from $157.01 to $157.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. F7. Represents the weighted average price of shares sold at prices that ranged from $158.18 to $158.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
8. F8. Represents the weighted average price of shares sold at prices that ranged from $159 to $159.97. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
9. F9. Represents the weighted average price of shares sold at prices that ranged from $160.01 to $160.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
10. F10. Represents the weighted average price of shares sold at prices that ranged from $161.31 to $161.95. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
11. F11. Represents the weighted average price of shares sold at prices that ranged from $162 to $162.59. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

ADS sold: 1,000 ADS Price range: $154.62–$162.59 per ADS Post-transaction holdings: 7,654 ADS +2 more

5 metrics

ADS sold 1,000 ADS Total American depositary shares sold on April 28, 2026

Price range $154.62–$162.59 per ADS Weighted average sale price ranges from footnotes

Post-transaction holdings 7,654 ADS Directly owned by CSO after the reported sales

Single largest block 380 ADS at $159.4192 Largest individual tranche of open-market sales

Trading plan adoption date December 10, 2025 Date Rule 10b5-1 trading plan was adopted

Key Terms

American depositary share, Rule 10b5-1 trading plan, weighted average price

3 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001 per share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"Represents the weighted average price of shares sold at prices that ranged from $154.62 to $154.78"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BLTE report for its Chief Scientific Officer?

Belite Bio reported that Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares in open-market trades on April 28, 2026. The sales were broken into several small transactions at different prices but all occurred on the same date.

At what prices did the Belite Bio (BLTE) CSO sell his ADS?

The Chief Scientific Officer’s 1,000 American depositary shares were sold at weighted average prices ranging from $154.62 to $162.59 per ADS. Individual trades within each range occurred at slightly different prices around those averages, as disclosed in the filing’s footnotes.

Was the BLTE insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing for these transactions.

How many Belite Bio ADS does the CSO hold after these reported sales?

After completing the April 28, 2026 transactions, Chief Scientific Officer Nathan L. Mata directly owned 7,654 American depositary shares. This post-transaction holding level is disclosed in the Form 4 and shows he retained a meaningful equity stake in Belite Bio.

How many Belite Bio (BLTE) shares in total were sold in this Form 4?

Across all reported trades, the insider sold a total of 1,000 American depositary shares according to the transaction summary. Each ADS represents one ordinary share of Belite Bio, as stated in the filing’s explanatory footnote regarding the ADS structure.

What role does the insider who sold BLTE shares hold at Belite Bio?

The reporting person, Nathan L. Mata, serves as Belite Bio’s Chief Scientific Officer. This executive role typically oversees research and development activities, meaning his equity transactions can be of interest to investors tracking management’s alignment with shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATA NATHAN L.

(Last) (First) (Middle)

7708 MARKER ROAD

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	04/28/2026		S(2)		12	D	$154.6467(3)	7,654	D
American depositary share(1)	04/28/2026		S(2)		8	D	$155.3588(4)	7,646	D
American depositary share(1)	04/28/2026		S(2)		53	D	$156.6117(5)	7,593	D
American depositary share(1)	04/28/2026		S(2)		222	D	$157.487(6)	7,371	D
American depositary share(1)	04/28/2026		S(2)		62	D	$158.7107(7)	7,309	D
American depositary share(1)	04/28/2026		S(2)		380	D	$159.4192(8)	6,929	D
American depositary share(1)	04/28/2026		S(2)		120	D	$160.2742(9)	6,809	D
American depositary share(1)	04/28/2026		S(2)		89	D	$161.7207(10)	6,720	D
American depositary share(1)	04/28/2026		S(2)		54	D	$162.1424(11)	6,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.

3. Represents the weighted average price of shares sold at prices that ranged from $154.62 to $154.78. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $155.205 to $155.41. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $156.32 to $156.95. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

6. Represents the weighted average price of shares sold at prices that ranged from $157.01 to $157.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

7. Represents the weighted average price of shares sold at prices that ranged from $158.18 to $158.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

8. Represents the weighted average price of shares sold at prices that ranged from $159 to $159.97. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

9. Represents the weighted average price of shares sold at prices that ranged from $160.01 to $160.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

10. Represents the weighted average price of shares sold at prices that ranged from $161.31 to $161.95. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

11. Represents the weighted average price of shares sold at prices that ranged from $162 to $162.59. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Nathan L. Mata	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)